MedTrace Logo

Safety and Efficacy of Bepotastine Besilate Nasal Spray in the Treatment of Seasonal Allergic Rhinitis

NCT01277341 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 601

Last updated 2020-10-05

Study results available
· View outcomes & findings →

Summary

This is an efficacy study of bepotastine besilate nasal spray in seasonal allergic rhinitis.

Conditions

  • Seasonal Allergic Rhinitis

Interventions

DRUG

Bepotastine Besilate Nasal Spray 2% Twice a day

nasal spray

DRUG

Bepotastine Besilate Nasal Spray 3% Twice a day

nasal spray

DRUG

Bepotastine Besilate Nasal Spray 4% Twice a day

nasal spray

DRUG

Placebo Nasal Spray

nasal spray

Sponsors & Collaborators

  • Bausch & Lomb Incorporated

    lead INDUSTRY

Principal Investigators

  • Tim McNamara, PharmD · ISTA Pharmaceuticals, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-12-31
Primary Completion
2011-02-28
Completion
2011-05-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01277341 on ClinicalTrials.gov